Life sciences venture capital firm Sofinnova Partners has announced a collaboration with Amazon Web Services (AWS), to embed AI more deeply across its investment platform and portfolio companies.
The collaboration supports Sofinnova.AI, the firm’s initiative to integrate AI across its core activities, from sourcing and evaluating investments to supporting company building. At the centre of this effort is Sofia, Sofinnova’s AI platform, which will be extended beyond internal use to include a founder-facing version.
Sofinnova-backed startups will gain access to tailored AWS resources and technical enablement, helping them move faster from early research to development and commercialisation.
“AI is becoming central to how new therapies are discovered, developed, and brought to patients,” said Antoine Papiernik, chairman and managing partner at Sofinnova Partners.
“With Sofinnova.AI and Sofia, we are building capabilities that strengthen both our investment approach and the companies we back. Working with AWS reflects both the maturity of this effort and our conviction that the next generation of life sciences leaders will be built differently.”
Life sciences companies face barriers in adopting AI, from infrastructure costs to fragmented tools and workflows. This collaboration combines Sofia with AWS’s scalable cloud services built specifically for the life sciences industry, making these tools more accessible and practical for founders.
“We are proud to support the future of life sciences innovation through this collaboration,” said Dan Sheeran, VP and general manager, healthcare and life sciences at AWS.
“AWS has worked closely with the pharmaceutical and life sciences industry for nearly two decades, with 19 of the top 20 global pharmaceutical companies trusting us to power their most sensitive research workloads. By combining AWS’ industry-specific services and solutions with Sofinnova’s track record in building life sciences companies, this effort aims to help bring new therapies and solutions to market faster and at scale.”
A core part of the collaboration is the development of a founder-facing version of Sofia, built on AWS. Until now, Sofia has been used internally across Sofinnova’s strategies to analyse deal flow and generate insights across biotech, medtech, digital health, and sustainability. The expanded platform will give founders access to AI-driven tools for competitive landscape analysis, asset benchmarking, and partnership and licensing insights.
These workflows remain largely manual across the industry. By making them faster and more consistent, Sofinnova aims to help companies focus resources on scientific and clinical progress.
As demand for AI and compute continues to grow across life sciences, Sofinnova sees this as a structural shift in how companies are built. The collaboration reflects the firm’s long-term strategy to embed AI into both investment decisions and value creation, while lowering barriers for founders.